Fabrice Bonnet

Professor

Université de Rennes 1

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Fabrice Bonnet is a Professor at Université de Rennes 1 in France. His research primarily focuses on cardiovascular health, diabetes management, and nephrology, as evidenced by his recent publications on testosterone therapy's effects, diabetic kidney disease, and the impact of systemic therapies on glycaemic control in type 2 diabetes patients. He is dedicated to advancing clinical practice through real-world evidence studies and exploring associations between various health outcomes.

Articles (6)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2021

Year:

2020

Collaborators (1)

Oliver Kuss

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Fabrice Bonnet

Research Interests

Explore related searches

Contact this professor

About

Articles (6)

Testosterone therapy and the risk of atrial fibrillation, venous thromboembolism and cardiovascular events in cis men with hypogonadism and trans men

A review of the latest real‐world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?

The number of nephroprotection targets attained is associated with cardiorenal outcomes and mortality in patients with diabetic kidney disease. The CKD‐REIN cohort study

HbA1c trajectories over 3 years in people with type 2 diabetes starting second‐line glucose‐lowering therapy: The prospective global DISCOVER study

What are the factors associated with long‐term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0%) at initiation of second‐line therapy? Results from the DISCOVER study

Increased risk of type 2 diabetes in antidepressant users: evidence from a 6‐year longitudinal study in the E3N cohort

Collaborators (1)

Oliver Kuss

Make your next move.